In further coverage of this week's announcement of supplementary data from our Phase 1 clinical trial of AMP945, Amplia's Chief Scientific Officer, Dr Mark Devlin, spoke with Andrew Scott from Proactive to discuss the significance of these data.
Watch the video.
